PDE5A and myeloid sarcoma: Bodies of evidence derived mainly from high- or moderate-confidence Cochrane or PROSPERO-registered reviews, such as PDE5 inhibitors in SCI and selected psychobehavioral or physiotherapy interventions in MS and stroke, supported higher certainty ratings [50,53,56,58,59,61].